Dossier
Clive Meanwell
Coverage of Clive Meanwell in the Nexus archive.
- STAT+: Talawar bets bispecific approach can shake up eczema market
Talawar is leveraging a bispecific approach to potentially disrupt the eczema market. The article also highlights a SPAC for a bispecific maker, Moderna's advancing mRNA ambitions, and Clive Meanwell's perspective on AI's role in biotech drug design.
- STAT+: Investor Clive Meanwell on designing biotechs for population health, and AI’s role as a catalyst
Clive Meanwell, chairman of Population Health Partners, leveraged a competitive bidding war between Pfizer and Novo Nordisk for obesity startup Metsera, which reached a $10 billion offer. He now focuses on AI-driven solutions to address large-scale health challenges through innovative technologies and business models.